An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
This piece is about a growing interest in “longevity medicine” — treatments people hope will slow aging or extend healthy life. It notes how drugs that started as diabetes or weight-loss medicines, like Ozempic, have grabbed headlines and money, and how newer things like supplements linked to cellular energy (often called NAD+ boosters) are getting attention too. The story is really about the trend: more people, companies, and doctors are chasing ways to live longer and feel younger. One of the drugs people know is semaglutide, the active ingredient in Ozempic and Wegovy. It’s a medicine that mimics a gut hormone that helps control appetite and blood sugar. That’s why it can cause big weight loss in some people and is approved for diabetes and obesity. NAD+ is not a drug but a molecule your cells use to carry energy and help repair DNA. Some companies sell supplements that they say raise NAD+ levels to improve metabolism, energy and cell repair. The two examples are different: semaglutide is a proven medicine with clear effects in trials, while NAD+ boosters are more experimental. What the reporting shows is a mix. For semaglutide and similar drugs, large clinical trials and real-world use have demonstrated significant weight loss and better blood sugar control in many people. That’s why they became so popular and controversial — supply, cost, and side effects matter. For NAD+ and other “longevity” approaches, the evidence is thinner. There are some lab studies and small human trials suggesting possible benefits for cell metabolism or markers of aging, but results are preliminary and not definitive. The story highlights enthusiasm and investment more than conclusive proof that these approaches extend human lifespan. Why this matters is twofold. First, effective medicines like semaglutide can change public health quickly by reducing obesity and diabetes complications, which affects lots of people. Second, the growing hype around longevity products fuels a market where people spend money and hope on interventions that may or may not work. For consumers, that means new options but also the risk of disappointment or harm. Doctors, regulators, and investors are paying attention because the stakes are high: both for health outcomes and for where research dollars go. There are important caveats and risks. Diabetes drugs used for weight loss can cause nausea, stomach issues, and rare but serious problems; they also require medical supervision and are prescription-only. NAD+ supplements are often sold as dietary products with less regulatory oversight, so quality and dosing can vary and long-term safety is unclear. People with certain health conditions, pregnant people, or those on multiple medications should be cautious and consult a clinician before trying these treatments. Finally, popularity doesn’t equal proof: anecdote and social media buzz aren’t a substitute for rigorous trials. Bottom line: some medicines used today can produce real health benefits, but many “longevity” ideas are still unproven; be skeptical, check the evidence, and talk to a doctor before trying anything.
Source: Cape Town ETC